|
AstraZeneca PLC said on Wednesday new, prolonged follow-up results from the phase three Champion-MG trial showed that Ultomiris demonstrated long-term efficacy in adults with generalised myasthenia gravis.
Generalised myasthenia gravis is a rare and chronic autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness, AstraZeneca explained.
Symptoms may include disabling fatigue, slurred speech, difficulty swallowing and eating, double or blurred vision as well as episodes of respiratory failure.
Ultomiris demonstrated improvements in activities of daily living, muscle strength and quality of life. This was sustained through 60 weeks, the Cambridge, England-based pharmaceutical company said. The medication was also well tolerated throughout this analysis, AstraZeneca added.
Regulatory submissions for Ultomiris for the treatment of generalised myasthenia gravis are currently under review with multiple health authorities, including in the US, the European Union and Japan.
Shares in AstraZeneca closed down 0.3% at 10,307.29 pence on Wednesday in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
